Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. MATERIALS AND METHODS: Patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Investig
Main Authors: Chiba, Koki, Nomoto, Hiroshi, Nakamura, Akinobu, Cho, Kyu Yong, Yamashita, Kumiko, Shibayama, Yui, Miya, Aika, Kameda, Hiraku, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7858126/
https://ncbi.nlm.nih.gov/pubmed/32593203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13335
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados